Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6847342 | 0.78 | MEN1 (0.31) | — | |
| SCHEMBL2216342 | 0.70 | ALDH1A1 (0.32) | SMN1; SMN2 | |
| SCHEMBL964583 | 0.66 | ECE1 (0.58) | ECE1HTT | |
| SCHEMBL7749425 | 0.66 | ALDH1A1 (0.38) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL1062014 | 0.64 | ALDH1A1 (0.33) | — | |
| SCHEMBL29229819 | 0.64 | SMN1; SMN2 (0.51) | ECE1HPGDHTTSMN1; SMN2 | |
| SCHEMBL8191582 | 0.64 | HPGD (0.36) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL31674997 | 0.63 | MEN1 (0.32) | — | |
| SCHEMBL21986417 | 0.62 | EPHX2 (0.42) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL25217270 | 0.61 | LMNA (0.32) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10376593-B2 | Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri | Universite De Paris (FR) | 2019-08-13 | — | — | US | disclosed |
| US-9446109-B2 | Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-09-20 | — | — | US | disclosed |
| US-20150290331-A1 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | Universite De Paris (FR) | 2015-10-15 | — | — | US | disclosed |
| US-8124380-B2 | Oligo/polysaccharides bound to carrier; immunogens; monoclonal antibodies; chimeric antibodies; kits; host cells; transgenic plants/animals | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2012-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290331-A1 | GLYCOCONJUGATES AND THEIR USE AS POTENTIAL VACCINES AGAINST INFECTION BY SHIGELLA FLEXNERI | YBX1, HEXD, DDOST | ECE1 1922/4885HPGD 2461/4885HTT 3455/4885 |
| US-10376593-B2 | Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri | YBX1, HEXD, DDOST | ECE1 1922/4885HPGD 2461/4885HTT 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.